Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rigel Pharmaceuticals excels in sales, faces awareness challenges ahead

Rigel Pharmaceuticals demonstrated strong sales performance and efficient cost management in Q4 2022.
The company faces challenges in raising awareness, maintaining persistency, and reaching profitability.
Exploring market opportunities, partnerships, and collaborations position Rigel for future growth.
Competitive trial results and a focus on persistency drive Rigel's competitive edge in the market.

Rigel Pharmaceuticals excels in Q1 with REZLIDHIA and TAVALISSE, faces prescribing behavior challenges

Rigel Pharmaceuticals showcased strong Q1 performance, particularly with REZLIDHIA and TAVALISSE, while facing challenges in understanding prescribing behavior.
The company's focus on differentiated positioning, academic-community growth, and strategic partnerships presents promising opportunities for future expansion.
Financial stability, positive clinician feedback, and ongoing pipeline advancements position Rigel well for continued growth and success in the market.

Rigel Pharmaceuticals reports robust Q2 sales and strategic growth focus

Rigel Pharmaceuticals showcased strong sales performance and product efficacy in Q2, positioning for future growth.
Challenges in managing expenses and strategic decision-making require careful navigation for sustained profitability.
Exploration of new opportunities and continued focus on innovation present avenues for revenue growth and market expansion.
Financial stability, ongoing development programs, and positive market feedback underpin Rigel's strategic direction and growth potential.

Rigel Pharmaceuticals excels in Q3 sales, eyes pipeline expansion

Rigel Pharmaceuticals demonstrated robust sales growth in Q3, managed expenses effectively, and aims for financial breakeven through operational efficiency. The company's strategic focus on pipeline expansion and partnerships positions it well for future growth and innovation.

Rigel Pharmaceuticals posts record sales, eyes growth with Gavreto acquisition

Rigel Pharmaceuticals reported strong financial performance with record sales and net income in Q4 2023.
The acquisition of Gavreto presents growth opportunities in the oncology market.
Challenges include transitioning Gavreto to commercial operations and competition in the targeted therapy space.

Rigel Pharmaceuticals reports strong Q1 performance and growth opportunities

Rigel Pharmaceuticals demonstrated strong performance in Q1 2024 with robust demand for key products and strategic acquisitions.
While facing challenges such as inventory management and financial breakeven, the company is well-positioned for growth.
Opportunities lie in continued sales growth, clinical advancements, and portfolio expansion through in-licensing deals.

Rigel Pharmaceuticals excels in Q2 with strong sales and pipeline progress

Rigel Pharmaceuticals delivered a robust performance in Q2 2024, driven by commercial success, pipeline advancements, and financial discipline. While facing challenges in clinical trial strategies and competitive landscape, the company is well-positioned to capitalize on growth opportunities through product expansions and strategic partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a collaboration with CONNECT, an international collaborative network of pediatric cancer centers, to conduct a Phase 2 clinical trial to evaluate REZLIDHIA® (olutasidenib) in combination with temozolomide as maintenance therapy in newly diagnosed pediatric and young adult patients with high-grade glioma (HGG) harboring an isocitrate dehydrogenase-1 (IDH1) mutation.

Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma

Here, we discuss some reasons why buying Rigel Pharmaceuticals (RIGL) stock now may turn out to be a prudent move.

Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now

SOUTH SAN FRANCISCO, Calif. , Jan. 3, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 42nd Annual J.P.

Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BrightSpire Capital

BRSP and RIGL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 8, 2023.

Best Momentum Stock to Buy for December 8th

SOUTH SAN FRANCISCO, Calif. and HOUSTON , Dec. 8, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a multi-year strategic development collaboration to expand the evaluation of REZLIDHIA ®  (olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers.

Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers

RIGL's net loss continues to narrow, down to $5.7M in Q3'23. RIGL's patent infringement suit with Annora Pharma is in play, but I don't expect a near-term issue on Tavalisse market exclusivity, because the case will take time to play out. A return to stronger growth for Rezlidhia seems likely in subsequent quarters, which provides a near-term catalyst.

Rigel Pharmaceuticals: Push To Profitability Continues, But COVID Beacon Seems Extinguished

Aquestive Therapeutics Inc

Dutch Bros

NAPCO Security Technologies

Founder SPAC

AQST, BROS, NSSC, RIGL and RBT have been added to the Zacks Rank #1 (Strong Buy) List on November 28, 2023.

New Strong Buy Stocks for November 28th

Brainsway

BWAY, RIGL and BROS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 22, 2023.

Best Momentum Stocks to Buy for November 22nd

AvidXchange Holdings

Brinker International

ImmunoGen

RIGL, BWAY, AVDX, IMGN and EAT have been added to the Zacks Rank #1 (Strong Buy) List on November 22, 2023.

New Strong Buy Stocks for November 22nd

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary Raul Rodriguez - President & Chief Executive Officer Dean Schorno - Chief Financial Officer Dave Santos - EVP & Chief Commercial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Operator Greetings, and welcome to Rigel Pharmaceuticals Financial Conference Call for the Third Quarter of 2023.

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2023 Earnings Call Transcript

Third quarter 2023 Total Revenue of $28.1 million which includes record TAVALISSE® net product sales of $24.5 million and REZLIDHIA® net product sales of $2.7 million New data on olutasidenib in mIDH1 relapsed or refractory acute myeloid leukemia to be presented at ASH Annual Meeting Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update

-- Growing body of data on REZLIDHIA® (olutasidenib) in mIDH1 relapsed or refractory (R/R) acute myeloid leukemia (AML) patients -- -- New data on olutasidenib in patients with mIDH1 myelodysplastic syndromes/neoplasms (MDS) -- SOUTH SAN FRANCISCO, Calif. , Nov. 2, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the upcoming presentation of four posters highlighting data from their commercial and clinical-stage hematology-oncology portfolio at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, California and virtually.

Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2023 financial results after market close on Tuesday, November 7, 2023.

Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update

-- Provides Update on ACTIV-4 Host Tissue Trial -- SOUTH SAN FRANCISCO, Calif. , Oct. 11, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming oral presentation highlighting data from the FOCUS Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients without respiratory failure who have certain high-risk prognostic factors at IDWeek 2023 being held October 11-15, 2023, in Boston, MA and provided an update on the ACTIV-4 Host Tissue trial of fostamatinib in hospitalized patients with COVID-19.

Rigel Announces Presentation at the Upcoming IDWeek 2023

SOUTH SAN FRANCISCO, Calif. , Sept. 20, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 3:35 p.m.

Rigel to Present at the 2023 Cantor Global Healthcare Conference

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Ray Furey - EVP, General Counsel and Corporate Secretary. Raul Rodriguez - President and CEO Dave Santos - EVP and Chief Commercial Officer Dean Schorno - EVP and Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup, Inc. Kristen Kluska - Cantor Fitzgerald & Co. Joseph Pantginis - H.C.

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2023 Earnings Call Transcript

Second quarter 2023 Total Revenue of $26.9 million which includes TAVALISSE® net product sales of $21.3 million and REZLIDHIA® net product sales of $2.6 million Development programs continue to advance with completion of target enrollment in cohort 2 of Phase 1b trial of R289 in lower-risk MDS and initiation of Phase 2a trial of R552 in rheumatoid arthritis by partner, Eli Lilly Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update

bluebird bio

Etsy

While the idea of making it big with the winning lottery ticket sounds appealing to practically anybody, the reality is that you're better off targeting stocks with high returns. Don't get me wrong – this segment of the capital market presents incredible risks.

3 Stocks to Buy for Lottery Jackpot Style Returns

SOUTH SAN FRANCISCO, Calif. , July 25, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2023 financial results after market close on Tuesday, August 1, 2023.

Rigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business Update

Blade Air Mobility

Dragonfly Energy Holdings Corp

Canoo

Organogenesis Holdings

Rockwell Medical

The Metals Co

Interested in discovering the top penny stocks to invest in? You're certainly not the only one.

7 Cheap Penny Stocks to Buy According To Analysts, Targets Up To 1,090%

SOUTH SAN FRANCISCO, Calif. , July 5, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Durable remissions observed in patients relapsed or refractory to prior venetoclax-based regimens Data featured in a poster presentation at the European Hematology Association (EHA) 2023 Hybrid Congress SOUTH SAN FRANCISCO, Calif. , June 7, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced promising data from an analysis of the Phase 2 study evaluating REZLIDHIA® (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1)1, in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.

Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML

Review article examines the preclinical and clinical development, and the role of olutasidenib in the mIDH1 AML treatment landscape. Authors conclude, "The approval of olutasidenib is a critical addition to the mIDH1 AML treatment landscape with encouragingly durable responses.

Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood Advances

SOUTH SAN FRANCISCO, Calif. , June 1, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming poster presentation highlighting the Company's IRAK1/4 program at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2023, in Chicago, IL, and virtually.

Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting

SOUTH SAN FRANCISCO, Calif. , May 31, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present on Wednesday, June 7, 2023 at 2:30 p.m.

News for Rigel Pharmaceuticals Stock (RIGL)